Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

June 28, 2017

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
DRUG

Pamiparib

Administered by mouth as a capsule twice daily

DRUG

Temozolomide

TMZ at various doses administered by mouth as a capsule once daily.

Trial Locations (22)

2010

Saint Vincents Hospital Sydney, Darlinghurst

2050

Chris Obrien Lifehouse, Camperdown

3000

Peter Maccallum Cancer Centre, Melbourne

4101

Icon Cancer Centre South Brisbane, South Brisbane

10029

Mount Sinai Prime, New York

10467

Montefiore Medical Park At Eastchester Einstein Campus, The Bronx

28034

Hospital Universitario Ramon Y Cajal, Madrid

28040

Start Madrid Fundacion Jimenez Diaz, Madrid

28050

Centro Integral Oncologico Clara Campal, Madrid

37203

Sarah Cannon Cancer Center, Nashville

41009

Hospital Universitario Virgen de La Macarena, Seville

46010

Hospital Clinico Universitario de Valencia, Valencia

49503

Start Midwest, Grand Rapids

63110

Washington University in St Louis, St Louis

75230

Texas Oncology (Loop) Usor, Dallas

77030-4009

The University of Texas Md Anderson Cancer Center, Houston

08035

Hospital Universitario Vall Dhebron, Barcelona

08907

Ico H Duran I Reynals, Barcelona

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

NE7 7DN

Northern Centre For Cancer Care, High Heaton

NW1 2PG

University College Hospital, London

W1G 6AD

Sarah Cannon Research Institute Uk, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Myriad Genetics, Inc.

INDUSTRY

lead

BeiGene

INDUSTRY

NCT03150810 - Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter